Ridinilazole: A novel antimicrobial for clostridium difficile infection

Annals of Gastroenterology

Volumn 32, Issue 2, 2019, Pages 134-140

  Cho, Jonathan C ^a   Crotty, Matthew P ^b   Pardo, Joe ^c  

^a UNIVERSITY OF TEXAS AT TYLER   (United States)

^b METHODIST DALLAS MEDICAL CENTER   (United States)

^c North FL South GA Veterans Health System   (United States)

Author keywords

Clostridium difficile; Infectious diarrhea; Ridinilazole

Indexed keywords

CALGRANULIN; DNA 16S; FIDAXOMICIN; LACTOFERRIN; METRONIDAZOLE; RIDINILAZOLE; VANCOMYCIN;

ABDOMINAL PAIN; ACTINOBACTERIA; ANTIMICROBIAL ACTIVITY; BACTERICIDAL ACTIVITY; BACTEROIDES FRAGILIS; BACTEROIDETES; CELL GROWTH; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG SAFETY; FECES MICROFLORA; FIRMICUTES; HUMAN; INTESTINE FLORA; MIC50; MIC90; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; REVIEW;

EID: 85063618766     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: 10.20524/aog.2018.0336     Document Type: Review

References (46)

1. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-353.
2. O’Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28:1219-1227.
3. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012;55(Suppl 2):S88-S92.
4. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2013. http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf [Accessed 11 November, 2018].
5. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825-834.
6. He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013;45:109-113.
7. Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. J Infect 2013;66:115-128.
8. Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver 2014;8:1-6.
9. Borren NZ, Ghadermarzi S, Hutfless S, Ananthakrishnan AN. The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact. PLoS One 2017;12:e0176797.
10. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998;128:989-995.
11. Valiquette L, Cossette B, Garant MP, Diab H, Pépin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45(Suppl 2):S112-S121.
12. Dingle KE, Didelot X, Quan TP, et al; Modernising Medical Microbiology Informatics Group. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis 2017;17:411-421.
13. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 2017;17:990-1001.
14. Eyre DW, Walker AS, Wyllie D, et al; Infections in Oxfordshire Research Database. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012;55(Suppl 2):S77-S87.
15. Eyre DW, Cule ML, Wilson DJ, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 2013;369:1195-1205.
16. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 2012; 18(Suppl 6):21-27.
17. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:987-994.
18. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20(Suppl 2):1-26.
19. Louie TJ, Miller MA, Mullane KM, et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-431.
20. Crook DW, Walker AS, Kean Y, et al; Study 003/004 Teams. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012;55(Suppl 2):S93-S103.
21. Tickler IA, Goering RV, Whitmore JD, Lynn AN, Persing DH, Tenover FC; Healthcare Associated Infection Consortium. Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013. Antimicrob Agents Chemother 2014;58:4214-4218.
22. Bassères E, Endres BT, Khaleduzzaman M, et al. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother 2016;71:1245-1251.
23. Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents 2016;48:137-143.
24. Bassères E, Endres BT, Vickers R, et al. Transcriptome functional analysis of Clostridium difficile exposed to ridinilazole; insight into potential mechanism of action. In: Abstracts of the Twenty-seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 2017. Abstract EP0404, Blackwell, Hoboken, NJ, USA.
25. Vickers RJ, Storer R, Tinsley J, et al. SMT19969: Preclinical safety and pharmacokinetics of a novel antibiotic for Clostridium difficile infection. In: Abstracts of the Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 2013, Abstract P1656.
26. Vickers R, Robinson N, Best E, Echols R, Tillotson G, Wilcox M. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections. BMC Infect Dis 2015;15:91.
27. Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother 2013;57:4872-4876.
28. Corbett D, Wise A, Birchall S, et al. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. J Antimicrob Chemother 2015; 70:1751-1756.
29. Freeman J, Vernon J, Vickers R, Wilcox MH. Susceptibility of Clostridium difficile isolates of varying antimicrobial resistance phenotypes to smt19969 and 11 comparators. Antimicrob Agents Chemother 2016;60:689-692.
30. Snydman DR, McDermott LA, Thorpe CM, et al. In-vitro activity of ridinilazole and comparators against isolates of Clostridium difficile obtained from stools of patients as part of US Surveillance in 2014. In: American Society for Microbiology Microbe 2017, New Orleans, LA, USA, Abstract 235.
31. Snydman DR, McDermott LA, Thorpe CM, et al. Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin. J Antimicrob Chemother 2018;73:2078-2084.
32. Baines SD, Crowther GS, Freeman J, Todhunter S, Vickers R, Wilcox MH. SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother 2015;70:182-189.
33. Blondeau JM, Shebelski SD, Vickers R. Mutant prevention concentration of SMT19969 against clinical isolates of Clostridium difficile. In: Abstracts of the Fifty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, 2014, Abstract F-245.
34. Vickers R, Tinsley J, Wilson F, et al. SMT19969: In vitro and in vivo evaluation of a novel antibiotic for Clostridium difficile infection. In: Abstracts of the Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 2013, Abstract P1655.
35. Hall D, Hinshaw R, Pillar C, et al. Resistance development studies with ridinilazole (RDZ) and Clostridium difficile. In: American Society for Microbiology Microbe 2016, Boston, MA, USA, Abstract 443.
36. Bassères E, Rashid T, Endres BT, et al. In vitro selection of Clostridium difficile resistance mutants exposed to ridinilazole. In: American Society for Microbiology Microbe 2017, New Orleans, LA, USA, Abstract 233.
37. Goldstein EJ, Citron DM, Tyrrell KL. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence. Antimicrob Agents Chemother 2014;58:1187-1191.
38. Best E, Vickers R, Wilcox MH. Effects of a novel antimicrobial (SMT19969) for treatment of Clostridium difficile infection (CDI) on gut flora. In: Abstracts of the Fifty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, Colorado, 2013, Abstract K-167.
39. Chang J, Kane A, Snydman DR, et al. Ridinilazole preserves major components of the intestinal microbiota during treatment of Clostridium difficile infection. In: American Society for Microbiology Microbe 2016, Boston, MA, USA, Abstract LB-116.
40. Mitra S, Chilton C, Freeman J, et al. Preservation of gut microbiome following ridinilazole versus fidaxomicin treatment of Clostridium difficile infection. In: ID Week, San Diego, CA, 2017, Abstract 1842.
41. Thorpe C, Kane A, Chang J, et al. Ridinilazole treatment for C. difficile infection preserves the intestinal microbiota of patients. In: Abstracts of the Twenty-seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 2017, Abstract P2049.
42. Sattar A, Thommes P, Payne L, Warn P, Vickers RJ. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI. J Antimicrob Chemother 2015;70:1757-1762.
43. Weiss W, Pulse M, Vickers R. In vivo assessment of SMT19969 in a hamster model of Clostridium difficile infection. Antimicrob Agents Chemother 2014;58:5714-5718.
44. Vickers RJ, Tillotson GS, Nathan R, et al; CoDIFy study group. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis 2017;17:735-744.
45. Vicker RJ, Yan K, Li Y. Ridinilazole for Clostridium difficile infection (CDI)-reductions in calprotectin and lactoferrin during therapy. In: American Society for Microbiology Microbe 2016, Boston, MA, USA, Abstract 441.
46. Douce G, Goulding D. Refinement of the hamster model of Clostridium difficile disease. Methods Mol Biol 2010;646:215-227.